NRTX-1001

NRTX-1001 is a regenerative neural cell therapy composed of human MGE-type inhibitory GABAergic interneurons derived from pluripotent stem cells. It is designed as an off-the-shelf, one-time administration therapy for the treatment of drug-resistant focal epilepsy, particularly mesial temporal lobe epilepsy (MTLE). The therapy works by delivering fully differentiated interneurons that secrete the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) directly into the seizure focus in the brain. These cells are intended to integrate into local neural circuits, persist long-term, and provide sustained GABAergic inhibition to repair hyper-excitable neural networks and suppress seizures without tissue-destructive procedures. NRTX-1001 is currently being evaluated in Phase 1/2 clinical trials for drug-resistant unilateral and bilateral MTLE. Preclinical studies have also suggested potential applications in Alzheimer’s disease by targeting subclinical epileptiform activity in the temporal lobe[3][5][6][8].

Other names

inhibitory interneuronsGABAergic interneurons